First‐line treatments for hepatitis C
First‐line treatments for hepatitis C
复制标题
丙型肝炎的一线治疗
DOI：
--
复制
发表时间：
2011
影响因子：
7.6
通讯作者：
D. Maratea
中科院分区：
文献类型：
--
作者：
A. Messori;F. Del Santo;D. Maratea
另一位在12年后去世。所有患者均接受持续抗凝治疗。8例EHPVT和MPD患者（5例男性，平均年龄55岁）中，5例有ET， 2例有PMF， 1例有PRV。入院时，所有患者均有门静脉高压征象，其中5例出现肠系膜上静脉血栓形成。经过平均1.8年（0.2-6年）的观察，他们都存活了下来。所有患者均接受持续抗凝治疗。非肝硬化门静脉高压是一种未被充分认识的实体，它与肝硬化非常相似，需要强烈的怀疑指数来诊断。几乎所有的PRV病例以及大约一半的ET和PMF病例中都发现了JAK2V617F突变。然而，JAK2V617F存在于所有接受突变评估的患者中，包括ET和PMF患者，其他研究人员最近也报道了这一发现。普遍存在的JAK2V617F可能表达更具侵袭性的表型，在这些不同的部位增加血栓形成的风险。总之，JAK2V617F评估在存在内脏静脉血栓形成的骨髓增生性疾病的早期诊断和管理中具有独特的作用。
another died after 12 years. All were on continuous anticoagulation therapy. Among eight patients with EHPVT and MPD (5 male, mean age 55 years), five had ET, two had PMF and one had PRV. On admission, all had signs of portal hypertension and five experienced superior mesenteric vein thrombosis. They are all alive after a mean period of 1.8 years (range, 0.2–6 years) of observation. All patients have been receiving continuous anticoagulation therapy. Non-cirrhotic portal hypertension is an under-recognised entity that closely mimics cirrhosis and needs a strong index of suspicion for the diagnosis. JAK2V617F mutation is found in nearly all cases of PRV and about half the cases of ET and PMF. However, JAK2V617F was present in all patients assessed for the mutation, including those with ET and PMF, a finding reported recently also by other investigators. The ubiquitous presence of JAK2V617F may express a more aggressive phenotype with an increased risk of thrombosis at these distinct sites. In conclusion, JAK2V617F assessment has a unique role in early diagnosis and consequently management of myeloproliferative disorders in the presence of splanchnic vein thrombosis.